BioCryst Pharmaceuticals, Inc. (BCRX)

In the past six months, BioCryst Pharmaceuticals' stock (BCRX) has experienced several notable events, including the report of Q1 2026 financial results showing a GAAP operating loss of $701.6 million, primarily due to a significant non-cash charge. ORLADEYO net revenue for Q1 2026 was $148.3 million, an 11% year-over-year increase, and total revenue reached $156.4 million. The company reaffirmed its full-year 2026 guidance for global ORLADEYO net revenue of $625 million to $645 million and total revenue of $635 million to $660 million. A licensing agreement in May 2026 with an Irish affiliate of Neopharmed Gentili for European commercial rights to navenibart included a $70 million upfront payment and potential milestones up to $275 million. In February 2026, BioCryst reported strong Q4 2025 earnings, with EPS soaring to $1.12 and revenue tripling to approximately $406.6 million. The company also finalized the $700 million acquisition of Astria Therapeutics in January 2026. Analyst ratings have seen some adjustments, and the stock's 52-week trading range has been between $6.00 and $11.31.

Demand seasonality for BioCryst's products varies. For RAPIVAB, demand is unpredictable and influenced by the flu season. For ORLADEYO, the company has noted "normal seasonality in revenue that follows first quarter prescription reauthorizations." The first quarter may experience some fluctuations in demand and revenue for ORLADEYO due to seasonal headwinds.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing oral small-molecule and injectable protein therapeutics for rare and serious diseases. The company operates within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry, addressing unmet medical needs in rare diseases. Its major commercialized product is ORLADEYO (berotralstat), an oral, once-daily plasma kallikrein inhibitor approved for prophylaxis to prevent hereditary angioedema (HAE) attacks. Another key product is RAPIVAB (peramivir injection), an antiviral drug approved for the treatment of acute uncomplicated influenza. BioCryst also has a pipeline of investigational drugs, including navenibart, BCX17725, and early-stage discovery programs.

BioCryst Pharmaceuticals is headquartered in Durham, North Carolina, with a Discovery Center of Excellence in Birmingham, Alabama. The company maintains a global presence with other regional offices. Its products have international reach, with peramivir approved in Japan, Korea, and China, and ORLADEYO approved in over 45 countries globally. A recent licensing agreement for navenibart also extends its commercialization potential into Europe.

BioCryst Pharmaceuticals emphasizes its commitment to discovering, developing, and delivering treatments for patients with rare diseases, aiming to have an extraordinary impact on their lives, which contributes positively to its brand reputation. A manufacturing issue delaying the first product fulfillment for ORLADEYO pellets for pediatric use was disclosed in May 2026, but is not expected to affect its 2026 revenue guidance. A potential buyout rumor in March 2026 caused a temporary stock surge but was treated as speculative. Jim Cramer advised investors to "just stay away" from the stock in February 2026, citing its long history of poor performance.

BioCryst Pharmaceuticals' ownership structure is predominantly institutional, with institutional investors holding over 70% of the outstanding shares. There are 296 institutional owners and shareholders holding a total of 250,993,463 shares. Major institutional investors include Vanguard Group Inc., BlackRock, Inc., RA Capital Management, L.P., Deerfield Management Company, L.P., and State Street Corp. Individual insiders also maintain substantial ownership stakes, accounting for 3.28% of insider ownership.